Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
Posted on August 13, 2009 at 5:42 pm by admin · Permalink
· Leave a comment
In: Chief Executive Officer, Emergent Bioslutions, Fuad, Fuad El-Hibri, Shareholder, United States, Washington D.C · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine
In: Chief Executive Officer, Emergent Bioslutions, Fuad, Fuad El-Hibri, Shareholder, United States, Washington D.C · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine
EMERGENT BIOSOLUTIONS ANNOUNCES RESULTS FROM ANNUAL MEETING OF STOCKHOLDERS
ROCKVILLE, MD, June 14, 2007—Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today the results of the company’s 2007 annual meeting of stockholders, which took place today at the Hyatt Regency Bethesda at 10:00 am Eastern.
There were present, in person or represented by proxy, the holders of more than a majority of the shares [...]
Posted on July 15, 2009 at 7:10 am by admin · Permalink
· Leave a comment
In: Uncategorized · Tagged with: Anthrax, Anthrax vaccines, Business, Company, Emergent BioSolutions, Health, Infectious disease, US Food and Drug Administration
In: Uncategorized · Tagged with: Anthrax, Anthrax vaccines, Business, Company, Emergent BioSolutions, Health, Infectious disease, US Food and Drug Administration